CircRNA_0044556 diminishes the sensitivity of triple‑negative breast cancer cells to adriamycin by sponging miR‑145 and regulating NRAS

Chen,Jingjing; Shi,Peng; Zhang,Jinghua; Li,Yufeng; Ma,Jie; Zhang,Yudong; Liu,Hong

doi:10.3892/mmr.2021.12567

CircRNA_0044556 diminishes the sensitivity of triple‑negative breast cancer cells to adriamycin by sponging miR‑145 and regulating NRAS

Authors:
- Jingjing Chen
- Peng Shi
- Jinghua Zhang
- Yufeng Li
- Jie Ma
- Yudong Zhang
- Hong Liu
View Affiliations

Affiliations: The Second Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin 300060, P.R. China, The Second Department of Urology Surgery, Tangshan People's Hospital, Tangshan, Hebei 063000, P.R. China, Department of Breast Health Care, Maternal and Child Care Service Centre, Tangshan, Hebei 063000, P.R. China, Central Laboratory, Tangshan People's Hospital, Tangshan, Hebei 063000, P.R. China, The First Department of Breast Surgery, Tangshan People's Hospital, Tangshan, Hebei 063000, P.R. China, North China University of Science and Technology, Tangshan People's Hospital, Tangshan, Hebei 063210, P.R. China
Published online on: December 13, 2021 https://doi.org/10.3892/mmr.2021.12567
Article Number: 51
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

CircRNAs are associated with adriamycin (ADM) resistance in triple‑negative breast cancer (TNBC), but the mechanism is unknown. Reverse transcription‑quantitative PCR was applied to quantify circular RNA (circRNA)_0044556, microRNA (miR)‑145 and NRAS proto‑oncogene, GTPase (NRAS) in TNBC tissues and cells with or without ADM treatment. Following ADM treatment, the effects of circRNA_0044556 on the viability, ADM resistance, apoptosis and migration of TNBC cells were investigated by cell function experiments (Cell Counting Kit‑8, flow cytometry and Transwell assays). The targeting relationship between circRNA_0044556 and miR‑145 was investigated via bioinformatics analysis, dual‑luciferase reporter assay and RNA immunoprecipitation. The effects of the circRNA_0044556/miR‑145 axis on the TNBC cells were revealed by rescue experiments. Correlations among circRNA_0044556, miR‑145 and NRAS were analyzed by Pearson's correlation test. CircRNA_0044556 was highly expressed in TNBC tissues and cells with or without ADM‑resistance. The overexpression of circRNA_0044556 promoted cell viability, ADM‑resistance and migration, while inhibiting the apoptosis by sponging miR‑145. Upregulation of miR‑145 reversed the effects of circRNA_0044556 on the TNBC cells. CircRNA_0044556 was negatively correlated with miR‑145 yet positively correlated with NRAS, the target gene of miR‑145, in addition to the discovery suggesting the negative regulatory effects of circRNA_0044556 on miR‑145. CircRNA_0044556 diminished the sensitivity of TNBC cells to ADM via the miR‑145/NRAS axis.

View Figures

View References

1	Zuo T, Zeng H, Li H, Liu S, Yang L, Xia C, Zheng R, Ma F, Liu L, Wang N, et al: The influence of stage at diagnosis and molecular subtype on breast cancer patient survival: A hospital-based multi-center study. Chin J Cancer. 36:842017. View Article : Google Scholar : PubMed/NCBI
2	Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn HJ, Panel Members, André F, et al: Tailoring therapies-improving the management of early breast cancer: St gallen international expert consensus on the primary therapy of early breast cancer 2015. Ann Oncol. 26:1533–1546. 2015. View Article : Google Scholar : PubMed/NCBI
3	Kumar P and Aggarwal R: An overview of triple-negative breast cancer. Arch Gynecol Obstet. 293:247–269. 2016. View Article : Google Scholar : PubMed/NCBI
4	Parikh RR, Yang Q, Higgins SA and Haffty BG: Outcomes in young women with breast cancer of triple-negative phenotype: The prognostic significance of CK19 expression. Int J Radiat Oncol Biol Phys. 70:35–42. 2008. View Article : Google Scholar : PubMed/NCBI
5	Lehmann BD, Pietenpol JA and Tan AR: Triple-negative breast cancer: Molecular subtypes and new targets for therapy. Am Soc Clin Oncol Educ Book. e31–e39. 2015. View Article : Google Scholar : PubMed/NCBI
6	Gao D, Zhang X, Liu B, Meng D, Fang K, Guo Z and Li L: Screening circular RNA related to chemotherapeutic resistance in breast cancer. Epigenomics. 9:1175–1188. 2017. View Article : Google Scholar : PubMed/NCBI
7	Song J, Yin J, Bai Z, Zhang J, Meng H, Cai J, Deng W, Ma X and Zhang Z: The profile of serum microRNAs predicts prognosis for resected gastric cancer patients receiving platinum-based chemotherapy. Dig Dis Sci. 62:1223–1234. 2017. View Article : Google Scholar : PubMed/NCBI
8	Yang M, Li Y, Ruan Y, Lu Y, Lin D, Xie Y, Dong B, Dang Q and Quan C: CLDN6 enhances chemoresistance to ADM via AF-6/ERKs pathway in TNBC cell line MDAMB231. Mol Cell Biochem. 443:169–180. 2018. View Article : Google Scholar : PubMed/NCBI
9	Li Z, Chen Z, Hu G and Jiang Y: Roles of circular RNA in breast cancer: Present and future. Am J Transl Res. 11:3945–3954. 2019.PubMed/NCBI
10	Jahani S, Nazeri E, Majidzadeh AK, Jahani M and Esmaeili R: Circular RNA; a new biomarker for breast cancer: A systematic review. J Cell Physiol. 235:5501–5510. 2020. View Article : Google Scholar : PubMed/NCBI
11	Guo JU, Agarwal V, Guo H and Bartel DP: Expanded identification and characterization of mammalian circular RNAs. Genome Biol. 15:4092014. View Article : Google Scholar : PubMed/NCBI
12	Meng S, Zhou H, Feng Z, Xu Z, Tang Y, Li P and Wu M: CircRNA: Functions and properties of a novel potential biomarker for cancer. Mol Cancer. 16:942017. View Article : Google Scholar : PubMed/NCBI
13	Shen Z, Zhou L, Zhang C and Xu J: Reduction of circular RNA Foxo3 promotes prostate cancer progression and chemoresistance to docetaxel. Cancer Lett. 468:88–101. 2020. View Article : Google Scholar : PubMed/NCBI
14	Sang Y, Chen B, Song X, Li Y, Liang Y, Han D, Zhang N, Zhang H, Liu Y, Chen T, et al: circRNA_0025202 regulates tamoxifen sensitivity and tumor progression via regulating the miR-182-5p/FOXO3a axis in breast cancer. Mol Ther. 27:1638–1652. 2019. View Article : Google Scholar : PubMed/NCBI
15	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Akram M and Siddiqui SA: Breast cancer management: Past, present and evolving. Indian J Cancer. 49:277–282. 2012. View Article : Google Scholar : PubMed/NCBI
18	Yin Y, Wang X, Li T, Ren Q, Li L, Sun X, Zhang B, Wang X, Han H, He Y, et al: MicroRNA-221 promotes breast cancer resistance to adriamycin via modulation of PTEN/Akt/mTOR signaling. Cancer Med. 9:1544–1552. 2020. View Article : Google Scholar : PubMed/NCBI
19	Vasan N, Baselga J and Hyman DM: A view on drug resistance in cancer. Nature. 575:299–309. 2019. View Article : Google Scholar : PubMed/NCBI
20	Nikolaou M, Pavlopoulou A, Georgakilas AG and Kyrodimos E: The challenge of drug resistance in cancer treatment: A current overview. Clin Exp Metastasis. 35:309–318. 2018. View Article : Google Scholar : PubMed/NCBI
21	Liang Y, Song X, Li Y, Su P, Han D, Ma T, Guo R, Chen B, Zhao W, Sang Y, et al: circKDM4C suppresses tumor progression and attenuates doxorubicin resistance by regulating miR-548p/PBLD axis in breast cancer. Oncogene. 38:6850–6866. 2019. View Article : Google Scholar : PubMed/NCBI
22	Dou D, Ren X, Han M, Xu X, Ge X, Gu Y, Wang X and Zhao S: CircUBE2D2 (hsa_circ_0005728) promotes cell proliferation, metastasis and chemoresistance in triple-negative breast cancer by regulating miR-512-3p/CDCA3 axis. Cancer Cell Int. 20:4542020. View Article : Google Scholar : PubMed/NCBI
23	Jing L, Wu J, Tang X, Ma M, Long F, Tian B and Lin C: Identification of circular RNA hsa_circ_0044556 and its effect on the progression of colorectal cancer. Cancer Cell Int. 20:4272020. View Article : Google Scholar : PubMed/NCBI
24	Yamaguchi R, Lartigue L and Perkins G: Targeting Mcl-1 and other Bcl-2 family member proteins in cancer therapy. Pharmacol Therap. 195:13–20. 2019. View Article : Google Scholar : PubMed/NCBI
25	Tang YY, Zhao P, Zou TN, Duan JJ, Zhi R, Yang SY, Yang DC and Wang XL: Circular RNA hsa_circ_0001982 promotes breast cancer cell carcinogenesis through decreasing miR-143. DNA Cell Biol. 36:901–908. 2017. View Article : Google Scholar : PubMed/NCBI
26	Gao M, Miao L, Liu M, Li C, Yu C, Yan H, Yin Y, Wang Y, Qi X and Ren J: miR-145 sensitizes breast cancer to doxorubicin by targeting multidrug resistance-associated protein-1. Oncotarget. 7:59714–59726. 2016. View Article : Google Scholar : PubMed/NCBI
27	Ding Y, Zhang C, Zhang J, Zhang N, Li T, Fang J, Zhang Y, Zuo F, Tao Z, Tang S, et al: miR-145 inhibits proliferation and migration of breast cancer cells by directly or indirectly regulating TGF-β1 expression. Int J Oncol. 50:1701–1710. 2017. View Article : Google Scholar : PubMed/NCBI
28	Chen S, Li F, Xu D, Hou K, Fang W and Li Y: The function of RAS mutation in cancer and advances in its drug research. Curr Pharm Des. 25:1105–1114. 2019. View Article : Google Scholar : PubMed/NCBI
29	Druillennec S, Pouponnot C and Eychène A: NRAS-driven melanoma: A RAF can hide another. Mol Cell Oncol. 4:e13447582017. View Article : Google Scholar : PubMed/NCBI
30	Banys-Paluchowski M, Milde-Langosch K, Fehm T, Witzel I, Oliveira-Ferrer L, Schmalfeldt B and Müller V: Clinical relevance of H-RAS, K-RAS, and N-RAS mRNA expression in primary breast cancer patients. Breast Cancer Res Treat. 179:403–414. 2020. View Article : Google Scholar : PubMed/NCBI
31	Prior IA, Lewis PD and Mattos C: A comprehensive survey of Ras mutations in cancer. Cancer Res. 72:2457–2467. 2012. View Article : Google Scholar : PubMed/NCBI
32	Song YK, Wang Y, Wen YY, Zhao P and Bian ZJ: MicroRNA-22 suppresses breast cancer cell growth and increases paclitaxel sensitivity by targeting NRAS. Technol Cancer Res Treat. 17:15330338188099972018. View Article : Google Scholar : PubMed/NCBI
33	Li X, Liu Y, Zhang X, Shen J, Xu R, Liu Y and Yu X: Circular RNA hsa_circ_0000073 contributes to osteosarcoma cell proliferation, migration, invasion and methotrexate resistance by sponging miR-145-5p and miR-151-3p and upregulating NRAS. Aging (Albany NY). 12:14157–14173. 2020. View Article : Google Scholar : PubMed/NCBI